TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti–PD-1/anti–CTLA-4 immunotherapy
Heng-Jia Liu(Brigham and Women's Hospital), Elizabeth P. Henske(Brigham and Women's Hospital), Kwok‐Kin Wong(NYU Langone Health), Heng Du(Brigham and Women's Hospital), Arlene H. Sharpe(Brigham and Women's Hospital), Hilaire C. Lam(Brigham and Women's Hospital), Patrick H. Lizotte(Harvard University), Spencer Vaughan(Brigham and Women's Hospital), Maria C. Speranza(Dana-Farber Cancer Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Nicola Alesi(Brigham and Women's Hospital)
Cited by 74
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome
|Nature Immunology|2010|3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k